What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical effectiveness of nivolumab with chemotherapy is supported by the CheckMate-816 trial, which is a Phase 3 study demonstrating improved event-free and overall survival compared to neoadjuvant chemotherapy alone. Although there is no direct comparison with standard care, the indirect evidence suggests a significant clinical advantage, particularly for stage 3 NSCLC. The committee concluded that nivolumab plus chemotherapy is more effective for resectable NSCLC, indicating a clear clinical benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nivolumab with chemotherapy are reported to be below £20,000 per QALY gained, which is within the range typically considered acceptable by NICE. The committee noted that the likelihood of decision error was minimal, supporting the conclusion that the treatment is a cost-effective use of Healthcare resources.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document discusses the potential for improved outcomes with nivolumab plus chemotherapy, specific data on health-related quality of life improvements are not provided. The evidence primarily focuses on survival outcomes, and there are concerns regarding the utility values used in the economic model, which may not accurately reflect the patient experience.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of nivolumab with chemotherapy is generally acceptable, with manageable adverse events. The document indicates that the treatment is associated with serious adverse events, but these are considered manageable and do not significantly undermine the overall benefit of the therapy.
Was the drug compared against what payers expect? — Comparator Selection
The comparators selected for the economic evaluation, including neoadjuvant chemoradiotherapy, surgery alone, and adjuvant chemotherapy, align well with NICE’s scope and represent standard clinical practice. This indicates a strong rationale for the comparisons made in the submission.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in CheckMate-816 includes adults with resectable stage 1B to 3A NSCLC, which is relevant to the intended patient population. However, there are concerns regarding the generalizability of the trial results to the Healthcare, particularly due to the lack of UK recruitment and the demographic differences noted.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab with chemotherapy can be integrated into existing care pathways with manageable adjustments. The treatment fits within the current clinical practice for NSCLC, although some minor adaptations may be necessary for optimal implementation.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of adopting nivolumab with chemotherapy are considered manageable, with the potential for cost savings due to its cost-effectiveness. The economic model indicates that the treatment is likely to be resource-efficient, aligning with Healthcare budget considerations.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from the CheckMate-816 trial, which is a robust Phase 3 RCT. While there are some uncertainties regarding generalizability and the economic model, the overall evidence quality is deemed acceptable for decision-making.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding long-term survival extrapolation and the cure assumption used in the economic model. While the committee acknowledged that these uncertainties had been explored, they still represent significant considerations that could impact the overall assessment.
